Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)
Melina Arnold, Eileen Morgan, Aude Bardot, Mark J. Rutherford, Jacques Ferlay, Alana Little, Bjørn Møller, Oliver Bucher, Prithwish De, Ryan Woods, Nathalie Saint‐Jacques, Anna Gavin, Gerda Engholm, Michael Patrick Achiam, Geoff Porter, Paul M. Walsh, Sally Vernon, Serena Kozie, Agnihotram V. Ramanakumar, Charlotte Lynch, Samantha Harrison, Neil D. Merrett, Dianne L. O’Connell, Tom Mala, Mark Elwood, John Zalcberg, Dyfed Huws, David Ransom, Freddie Ian Bray, Isabelle Soerjomataram (2021). International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). , 71(8), DOI: https://doi.org/10.1136/gutjnl-2021-325266.
Article165 days agoUpdated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C. Heinrich, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Robin L. Jones, Yoon‐Koo Kang, Albiruni R. Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L. Siontis, P. H. Cox, Erika Davis, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. , 43(20), DOI: https://doi.org/10.1200/jco-24-02818.
Article21 days agoImatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Desmond Yip, John Zalcberg, Jean Yves Blay, Mikael Eriksson, David Espinoza, Timothy Price, Sandrine Marréaud, Antoîne Italiano, Neeltje Steeghs, Kjetil Boye, Craig Underhill, Val Gebski, John Simes, Hans Gelderblom, Heikki Joensuu (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. , 132(10), DOI: https://doi.org/10.1038/s41416-025-02983-w.
Article21 days agoINSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Michael C. Heinrich, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John Zalcberg, William M. Reichmann, Kam Sprott, Matthew L. Sherman, Sebastian Bauer, Suzanne George (2025). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 43(4_suppl), DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.tps848.
Article21 days agoOverall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
John Zalcberg, Robin L. Jones, Jean Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Erika Davis, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich (2024). Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.. , 42(3_suppl), DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.748.
Article21 days ago